Development of a Commercial Manufacturing Process for Vepdegestrant, an Orally Bioavailable PROTAC Estrogen Receptor Degrader for the Treatment of Breast Cancer
- 5 November 2024
- journal article
- research article
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 28 (11) , 4079-4090
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- PROTAC targeted protein degraders: the past is prologueNature Reviews Drug Discovery, 2022
- The PROTACtable genomeNature Reviews Drug Discovery, 2021
- Prey for the Proteasome: Targeted Protein Degradation—A Medicinal Chemist's PerspectiveAngewandte Chemie International Edition, 2020
- Small molecules, big impact: 20 years of targeted therapy in oncologyThe Lancet, 2020
- Small‐Molecule PROTACS: New Approaches to Protein DegradationAngewandte Chemie International Edition, 2016
- Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and StateJNCI: Journal of the National Cancer Institute, 2015
- Convergent Strategies in Total Syntheses of Complex TerpenoidsChemical Reviews, 2015
- “Imprinting” Catalytically Active Pd Nanoparticles onto Ionic‐Liquid‐Modified Al2O3 SupportsChemCatChem, 2013
- Innovative Chiral Resolution Using Enantiospecific Co-Crystallization in SolutionCrystal Growth & Design, 2012
- Trends in the development of chiral drugsDrug Discovery Today, 2004